Chen Lian, Jiang Yu-Huan, Li Mei-Yong, Huang Bo, Yuan Lei, Wan Jin-Hua, Qin Ting-Yu, Zeng Ting-Ting, Chen Qing-Gen
Department of Ultrasound Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Infect Drug Resist. 2024 Nov 13;17:5037-5047. doi: 10.2147/IDR.S478798. eCollection 2024.
The aim of the present study was to identify more effective laboratory markers to assess the severity of corona virus disease 2019 and predict the progression of the disease by collecting more laboratory markers and variables.
In this study, most risk factors, including epidemiological characteristics, blood cell counts, cytokines, and infection markers, were collected from 126 patients with COVID-19 to assess their predictive value.
The area under curve (AUC) of Albumin (Alb) to fibrinogen (Fib) ratio (AFR) (0.791), Lactate dehydrogenase (LDH) (0.792), myoglobin (MYO) (0.795), C-reactive protein (CRP) (0.801) and lymphocyte count (0.859) were higher than other markers to distinguish severe from non-severe patients in receiver operating characteristic (ROC) analysis. In the univariate logistic regression analysis, thirty-six out of 46 risk factors, including 34 laboratory markers, were significantly associated with increased odds of severe patients. Multivariate logistic regression analysis showed that the CD19+ lymphocyte count, MYO, LDH, and AFR were associated with increased odds of severe disease. Moreover, Lymphocyte count and AFR levels increased, LDH and CRP levels decreased during hospitalization in recovered severe patients, whereas severe lymphocytopenia and continuously increasing LDH levels were observed in deteriorated patients. AFR level increased and CRP level decreased before the disease worsened in the deteriorated patients; however, when the patients deteriorated, AFR decreased and CRP increased significantly.
CD19+ lymphocyte count, MYO, LDH, and AFR are independent biomarkers for early identification of severe COVID-19. Lymphocyte count, AFR, LDH, and CRP levels were helpful in predicting the clinical progression of the disease..
本研究的目的是通过收集更多实验室指标和变量,确定更有效的实验室标志物,以评估2019冠状病毒病的严重程度并预测疾病进展。
在本研究中,收集了126例新型冠状病毒肺炎患者的大多数危险因素,包括流行病学特征、血细胞计数、细胞因子和感染标志物,以评估其预测价值。
在受试者工作特征(ROC)分析中,白蛋白(Alb)与纤维蛋白原(Fib)比值(AFR)(0.791)、乳酸脱氢酶(LDH)(0.792)、肌红蛋白(MYO)(0.795)、C反应蛋白(CRP)(0.801)和淋巴细胞计数(0.859)的曲线下面积(AUC)高于其他标志物,用于区分重症和非重症患者。在单因素逻辑回归分析中,46个危险因素中的36个,包括34个实验室标志物,与重症患者的患病几率增加显著相关。多因素逻辑回归分析显示,CD19+淋巴细胞计数、MYO、LDH和AFR与重症疾病的患病几率增加相关。此外,康复的重症患者住院期间淋巴细胞计数和AFR水平升高,LDH和CRP水平降低,而病情恶化的患者则出现严重淋巴细胞减少和LDH水平持续升高。病情恶化的患者在疾病恶化前AFR水平升高,CRP水平降低;然而,当患者病情恶化时,AFR降低,CRP显著升高。
CD19+淋巴细胞计数、MYO、LDH和AFR是早期识别重症新型冠状病毒肺炎的独立生物标志物。淋巴细胞计数、AFR、LDH和CRP水平有助于预测疾病的临床进展。